NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cybin D/B/A Helus Pharma (HELP) Stock Analysis

Cybin D/B/A Helus Pharma (HELP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HELP

$10.78

−$0.16 (−1.46%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HELP with… →

HELP Key Statistics

As of Oct 21, 2026
Trading
Open
$11.03
Previous Close
$10.94
Day's Range
10.75–11.66
52-Week Range
3.76–15.15
Volume
920.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
$787.59M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$148.00M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
73.06M
1-Year Return
+78.18%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HELP closed at $10.78, +78.18% over 1 year.

Cybin D/B/A Helus Pharma (HELP) has a market capitalization of $787.59M.

In fiscal 2025, HELP reported revenue of $0.00.

HELP Stock Return by Calendar Year

Cybin D/B/A Helus Pharma (HELP) return since Sep 2019: what $10,000 became

1 year
$10,000 $17,818
+78.18%
5 years
$10,000 $1,433
−85.67%
Since Sep 2019
$10,000 $2,157
−78.43%

If you had invested $10,000 in Cybin D/B/A Helus Pharma (HELP) at the close on September 13, 2019, the earliest close on record here, it would have been worth $2,157 at the close on October 21, 2026: −78.43% in total, −19.42% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+31.78%
2025−7.26%
2024−43.39%
2023+38.05%
2022−75.25%
2021−19.46%
2020+13.27%
2019 (partial year)+0.00%

As of October 21, 2026.

HELP Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$148.00M—
2024$0.00−$81.61M—
2023$0.00−$78.08M—
2022$0.00−$47.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$142.59M−$148.00M—
2024$0.00—−$103.13M−$81.61M—
2023$0.00—−$78.84M−$78.08M—
2022$0.00—−$51.52M−$47.49M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cybin D/B/A Helus Pharma (HELP) carries a market capitalisation of $787.59M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 100.

The most recent close on file for HELP is $10.78, dated October 21, 2026. That is −$0.16 (−1.46%) against the previous close. The 52-week range on file runs from $3.76 to $15.15. The latest close sits 186.7% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $148.00M. Trailing earnings per share are −4.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +78.18%. Across 5 years the annualized return works out at −32.20%. The reported beta is 0.54. Daily returns over the trailing 7 years annualize to a volatility of 332.56%.

Growth & Income

The record shows no dividend for HELP.

So far in 2026 the total return is +31.78%. The strongest complete calendar year on file is 2023 at +38.05%; the weakest is 2022 at −75.25%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Cybin D/B/A Helus Pharma (HELP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cybin D/B/A Helus Pharma HELP $787.59M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cybin D/B/A Helus Pharma has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cybin D/B/A Helus Pharma

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Visit website →